Legacy Wealth Asset Management LLC Acquires Shares of 4,053 DexCom, Inc. (NASDAQ:DXCM)

Legacy Wealth Asset Management LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 4,053 shares of the medical device company’s stock, valued at approximately $315,000.

Several other large investors also recently added to or reduced their stakes in the stock. B. Riley Wealth Advisors Inc. boosted its position in DexCom by 4.3% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock valued at $445,000 after buying an additional 162 shares during the period. Crossmark Global Holdings Inc. lifted its position in shares of DexCom by 1.0% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after purchasing an additional 182 shares during the period. Riverview Trust Co lifted its position in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the period. Koa Wealth Management LLC lifted its position in shares of DexCom by 7.7% in the 3rd quarter. Koa Wealth Management LLC now owns 3,770 shares of the medical device company’s stock worth $253,000 after purchasing an additional 270 shares during the period. Finally, Freedom Investment Management Inc. lifted its position in shares of DexCom by 10.2% in the 3rd quarter. Freedom Investment Management Inc. now owns 3,035 shares of the medical device company’s stock worth $203,000 after purchasing an additional 281 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.30% of the stock is currently owned by corporate insiders.

DexCom Trading Down 0.5 %

Shares of DexCom stock opened at $84.38 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm has a fifty day moving average price of $78.17 and a 200 day moving average price of $78.22. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock has a market cap of $32.96 billion, a PE ratio of 50.53, a price-to-earnings-growth ratio of 2.00 and a beta of 1.12.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on DXCM. Raymond James lowered their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Wells Fargo & Company increased their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and raised their target price for the company from $86.00 to $104.00 in a research note on Thursday. Finally, Sanford C. Bernstein raised their target price on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.29.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.